Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
MINDACT proved that among women with early breast cancer classified as high clinical risk but low genomic risk by MammaPrint, forgoing adjuvant chemotherapy still delivers excellent distant metastasis–free survival at five years. The 70-gene signature can safely reclassify nearly half of clinically high-risk patients away from chemotherapy. This trial established Level I evidence for genomic-guided chemotherapy de-escalation and changed adjuvant treatment algorithms worldwide.
Key Result: 5-year survival without distant metastasis (primary-test population, no chemotherapy) — 94.7% (95% CI, 92.5 to 96.2). Noninferiority boundary of 92% crossed — primary objective met.
Safety Signal: No safety data were reported in this publication.
✅ Patient Eligibility
Must Have:
- Histologically confirmed primary invasive breast cancer (T1, T2, or operable T3)
- Node-negative or 1–3 positive axillary nodes
- Age 18–70 years
- Discordant clinical and genomic risk (for randomization)
Cannot Have:
- ≥4 positive axillary nodes
- Age >70 years
- Non-operable disease
💊 Treatment Approach
This trial tested a diagnostic strategy, not a drug. Treatment was determined by risk classification:
High Clinical Risk / Low Genomic Risk (Randomized)
- Genomic risk arm: No chemotherapy; endocrine therapy if HR-positive
- Clinical risk arm: Adjuvant chemotherapy + endocrine therapy if HR-positive
Low Clinical Risk / High Genomic Risk (Randomized)
- Genomic risk arm: Adjuvant chemotherapy + endocrine therapy if HR-positive
- Clinical risk arm: No chemotherapy; endocrine therapy if HR-positive
Adherence: Overall 86% across discordant groups.
Mechanism: MammaPrint is a 70-gene expression profile assay that classifies early breast cancers into low or high genomic risk based on gene expression patterns associated with distant metastatic potential [2].
⚠️ Safety Snapshot
No safety or adverse event data were reported in this publication.
📊 Key Numbers
Median follow-up: 5.0 years
Primary Endpoint
| Outcome | Primary-Test Population (N=644) |
|---|---|
| 5-year survival without distant metastasis | 94.7% (95% CI, 92.5–96.2) |
| Noninferiority threshold | ≥92% lower CI boundary |
| Result | Met — lower boundary 92.5% |
Secondary Endpoints — High Clinical Risk / Low Genomic Risk (ITT)
| Outcome | Chemotherapy (n=749) | No Chemotherapy (n=748) | HR (95% CI) | P-value |
|---|---|---|---|---|
| 5-yr DMFS | 95.9% | 94.4% | 0.78 (0.50–1.21) | 0.27 |
Per-Protocol — High Clinical Risk / Low Genomic Risk
| Outcome | Chemotherapy (n=636) | No Chemotherapy (n=592) | HR (95% CI) | P-value |
|---|---|---|---|---|
| 5-yr DMFS | 96.7% | 94.8% | 0.65 (0.38–1.10) | 0.11 |
| 5-yr DFS | 93.3% | 90.3% | 0.64 (0.43–0.95) | 0.03 |
| 5-yr OS | 98.8% | 97.3% | 0.63 (0.29–1.37) | 0.25 |
All Enrolled Patients by Risk Group
| Risk Group | 5-yr DMFS |
|---|---|
| Low clinical / Low genomic (n=2745) | 97.6% |
| Discordant groups | ~95% |
| High clinical / High genomic (n=1806) | 90.6% |
🔬 Key Comparator Context
| Trial | Test | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| MINDACT | MammaPrint (70-gene) | Early BC, T1–T3, N0–N1 | 5-yr DMFS (noninferiority) | 94.7% (LCI 92.5% > 92%) | [1] |
| TAILORx | Oncotype DX (21-gene) | HR+/HER2−, N0; RS 11–25 | Invasive DFS (noninferiority) | See [4] | [4] |
| RxPONDER | Oncotype DX (21-gene) | HR+/HER2−, N1–3; RS 0–25 | Invasive DFS | See [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
Node-negative (HC/LG): 5-yr DMFS 95.7% (chemo) vs 93.2% (no chemo) — small absolute difference Node-positive (HC/LG): 5-yr DMFS 96.3% (chemo) vs 95.6% (no chemo) — minimal difference ER+/HER2−/node-neg (HC/LG): 5-yr DMFS 95.5% (chemo) vs 93.9% (no chemo) — similar pattern
Subgroup analyses were exploratory and not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | MammaPrint cleared (510(k)); updated indication 2017 to include 1–3 positive nodes [2] |
| EMA | CE-marked for clinical use |
⚠️ Verify current regulatory status before clinical use.
NCCN: MammaPrint included as validated gene expression assay for adjuvant therapy decision-making in HR+/HER2− early breast cancer [3].
⚡ Grey Zones
- Patients with >3 positive nodes were excluded — do not extrapolate to heavy nodal burden
- HER2-positive patients included but not separately analyzed in detail — genomic risk relevance unclear in HER2+ disease
- 5-year follow-up may be insufficient for HR+ breast cancer with known late recurrence risk
- Per-protocol DFS showed ~3% absolute difference favoring chemotherapy (P=0.03) — shared decision needed
- No safety data reported — cannot perform formal risk-benefit assessment within this trial
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Cardoso F, van 't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016;375:717-729. doi:10.1056/NEJMoa1602253
- MammaPrint 510(k) Summary. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
- Sparano JA, Gray RJ, Makower DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379:111-121. doi:10.1056/NEJMoa1804710
- Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021;385:2336-2347. doi:10.1056/NEJMoa2108873